-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Myeloproliferative/Myelodysplastic Overlap Syndromes: Diagnosis and Treatment

Program: Education Program
Session: Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose?
Hematology Disease Topics & Pathways:
Diseases, Non-Biological, CMML, Therapies, chemotherapy, Myeloid Malignancies
Monday, December 7, 2020, 8:55 AM-9:00 AM

Mrinal M. Patnaik, MD, MBBS

Division of Hematology, MAYO, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN

Disclosures: No relevant conflicts of interest to declare.

OffLabel Disclosure: Tipifarnib, Ruxolitinib, Tagraxofusp, Lenzilumab

Previous Presentation | Next Presentation >>